February 13, 2024
RegMed Investors (RMi) Closing Bell: CPI infused dominoes topple the cell and gene therapy sector
February 12, 2024
RegMed Investors (RMi) Closing Bell: testing, testing, testing the flight plan request
February 9, 2024
RegMed Investors (RMi) Closing Bell: hang-on to reward prospects for a while
February 8, 2024
RegMed Investors (RMi) Closing Bell: share prices rides on the sector’s merry-go-round
February 7, 2024
RegMed Investors (RMi) Closing Bell: The RegMed sector was stuck with sentiment diarrhea
February 6, 2024
RegMed Investors (RMi) Closing Bell: electronic trader were not conflicted, saw the decline, popped the cork to carbonate some fizz in the sector
February 5, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy sector passes more gas
February 2, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy sector fluctuates what’s different?
February 1, 2024
RegMed Investors (RMi) Closing Bell: back on the roller-coaster
January 31, 2024
RegMed Investors (RMi) Closing Bell: When you are a cell and gene therapy believer, the benefit of the doubt is immeasurable – the sector is oversold
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.